Maegim한국어

디티앤씨알오

383930KOSDAQSector: Pharma & Biotech
₩1,710 1.50%Market cap ₩21.9BAs of Jul 21, 2026 close · updated once daily
D
Grade D39 ptsTop 72% of 2,523 stocks
Financial strength
24.6
Growth momentum
53.5
Price attractiveness
45.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

24.6
How much debt does it carry relative to equity?
Debt-to-equity ratio
260.2%
Below median · Top 93.3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
51.9%
Below median · Top 92.5% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-12.0%
Below median · Top 57.4% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
-11.1%
Below median · Top 58.3% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original

2

Growth momentum

53.5
How much did revenue grow in a year?
Revenue growth (YoY)
32.7%
Above median · Top 17.1% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
2.8%
Below median · Top 58.5% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
49.2%
Above median · Top 19.4% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-208.5%
Below median · Top 91.1% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original

3

Price attractiveness

45.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
Loss-making (P/E not computable)
Below median · Top 74.2% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.87x
Above median · Top 35.6% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15